Radiopharm Theranostics RADX
NASDAQ RADX
$1.44 -0.18 (-11.11%)
As of: Oct 1, 2026 · 10:36 AM EDT

Radiopharm Theranostics (RADX) Short term Debt (2024 - 2026)

Updated

Radiopharm Theranostics' Short term Debt came in at $48,668 for fiscal Q4 2026 (quarter ended Jun 30, 2026), up 122.1% from $21,911 a year earlier.

Analysis

Radiopharm Theranostics (RADX) Short term Debt (2024 - 2026) Analysis & Trends

At the end of FY2026 (ended Jun 30, 2026), Radiopharm Theranostics' Short term Debt was $46,596, down 98.6% from FY2025.

  • Going back by fiscal year, Short term Debt was $3.42 million in FY2025 (-45.9%) and $6.32 million in FY2024.
  • The fiscal Q4 2026 figure represents the highest quarterly Short term Debt since fiscal Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Radiopharm Theranostics 5.74 Bn 5.70 Bn 186,835.86
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 48,667.67
Jun 30, 2025 21,911.38
Dec 31, 2024 2.24 Mn
Jun 30, 2024 41,645.00
API Access

Radiopharm Theranostics Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=RADX&period=max&api_key=YOUR_API_KEY